Catherine Nipper
Women's Health · Plano, TXNPI 1962878884
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Pfizer at 47.6% of the total. Reporting peaked in 2023 at $3,902 and has fallen 76.4% since, to $920 in 2025. Among women's health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 218 payments — averaging $36.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$4K
- AbbVie$1K
- Astellas Pharma US Inc$452
- Mayne Pharma Commercial LLC$334
- Exeltis, USA Inc.$324
- Organon$253
- plus $2K from 24 others
What the payments were for
- Speaking & faculty fees$1,95025%
- Travel & lodging$1,16615%
- Food & beverage$4,54658%
- Education$1892%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 32 | $3,737 |
| AbbVie | 47 | $1,100 |
| Astellas Pharma US Inc | 17 | $452 |
| Mayne Pharma Commercial LLC | 17 | $334 |
| Exeltis, USA Inc. | 17 | $324 |
| Organon | 13 | $253 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $211 |
| Lilly USA, LLC | 6 | $189 |
| Millicent US Inc | 9 | $163 |
| Sumitomo Pharma America, Inc. | 7 | $134 |
| Ascend Therapeutics US, LLC | 3 | $126 |
| Hologic Sales And Service, LLC | 3 | $109 |
| Sage Therapeutics, LLC | 6 | $98 |
| Therapeuticsmd, Inc. | 6 | $94 |
| Novo Nordisk | 4 | $88 |
| Myovant Sciences Inc. | 4 | $87 |
| Bayer | 3 | $55 |
| Biohaven Pharmaceuticals, Inc. | 2 | $36 |
| Evofem Biosciences, Inc. | 2 | $36 |
| Axonics, Inc. | 2 | $31 |
| Avion Pharmaceuticals | 2 | $31 |
| Integra Lifesciences Corporation | 2 | $27 |
| American Regent | 1 | $26 |
| Johnson & Johnson | 1 | $19 |
| Boston Scientific | 1 | $18 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $17 |
| Baxter Healthcare | 1 | $16 |
| Cumberland Pharmaceuticals, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYFEMBREE$3,375
- NURTEC ODT$125
- Orilissa$125
- UBRELVY$124
- ZEPBOUND$121
- ANNOVERA$118
- NEXTSTELLIS$118
- ESTROGEL$103
- ORIAHNN$102
How this compares
$7,851 in reported general payments places this provider in the 95th percentile of 609 women's health providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 24 | $1,036 |
Paid to pharmacies, not to this prescriber.
Other women's health in Plano
- Evelyn TingGrapevine$89K
- Christina TrumanWaco$70K
- Kayla CastanedaEl Paso$53K
- Shelagh LarsonFort Worth$43K
- Amanda ArmondAustin$17K
- Joann St PierreHouston$15K
- Christina BlancoEl Paso$14K
- Ricshonda MilburnGalveston$13K
- Sandra EastlingLubbock$12K
- Lori WinkHouston$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.